Skip to main content
  • Blog

Why Patient Dropout isn’t a Patient Problem

Patient dropout in clinical trials is not typically the result of low motivation or an unwillingness to make the sacrifices that study participation may require. Yet these are often the explanations researchers reach for when attrition becomes a persistent challenge.1 

Instead of shifting responsibility onto patients, it is time that the industry reflects inwards and challenges itself to better understand what drives both enrollment and engagement throughout a clinical trial. 

Why patients become willing to participate in clinical research 

To understand why patients may drop out of a trial, it is key to understanding what may have motivated or influenced their decision to enroll in the first place: 

What motivates patients to participate? 
Helping advance treatment options for the condition they live with is the most commonly cited reasons patients choose to participate in clinical trials.2 Many patients see clinical research as an opportunity to potentially benefit from treatment while also contributing to the development of therapies that could improve care for future patients facing the same condition.1 

What encourages underrepresented populations to participate? 
Trust is one of the most important factors influencing participation among historically underrepresented populations. While there is no single solution to improving representation in clinical research, community engagement consistently emerges as a critical way to build that trust. Familiar healthcare environments and strong community connections can help raise awareness, foster confidence, and support participation. 3 

How does communication influence patient enrollment and retention? 
Communication with patients should be considered before a trial is even designed. 

Including patient input in trial design has been shown to mitigate patient dropout by ensuring the realities of living with a condition are reflected in study design decisions.4-6  This allows sponsors to identify potential participation barriers before the study begins while empowering healthcare providers (HCPs) to have realistic conversations about what participation will involve. It can also highlight opportunities to incorporate decentralized trial elements, such as telehealth appointments, remote monitoring technologies, or in-home visits, that reduce the burden of participation for both patients and caregivers. Yet even the most patient-friendly trial design can fall short if communication is poor. Patients should understand what is expected of them, what support is available and why their participation matters. Communication should be clear, culturally considerate, and free from unnecessary jargon. 

Why patients drop out 

Clinical trial dropout is often viewed as a patient problem, yet the challenges that contribute to attrition are frequently rooted in trial design. Time commitments, travel requirements, financial pressures, and family responsibilities can create barriers that make continued participation difficult or unsustainable.7 

Many patients are willing to overcome these challenges when they feel informed, supported, and connected to the purpose of the study. However, when participation burdens are compounded by poor communication, unmet expectations, or a lack of ongoing engagement, continued participation may no longer feel feasible. 

Attrition is rarely a sign that patients have lost interest in research. More often, it signals that the demands of participation have begun to outweigh the support and value patients experience throughout the study.8 

Community-based models improve enrollment and retention 

Community-based trial models address many of the factors that contribute to patient dropout. When combined with decentralized trial elements, such as in-home visits and telehealth appointments, they can significantly reduce common barriers including travel, cost, and time commitments. 

Yet their value extends beyond convenience. 

Community-based clinical trial teams are embedded in the communities they serve. As a result, they have a deeper understanding of local healthcare challenges, cultural considerations, and the day-to-day realities patients face outside of the trial setting. This enables more meaningful communication and helps build trust that is critical for long-term engagement. 

When patients feel understood and supported by the HCPs they interact with regularly, concerns can be identified earlier, expectations can be managed more effectively, and potential barriers to participation can be addressed before they lead to dropout. 

Ultimately, reducing patient dropout is not about asking patients to do more. It is about designing studies that better support the people who have already chosen to take part. By prioritizing communication, accessibility, and the patient experience, sponsors and trial teams can create studies that not only improve enrollment but also strengthen retention. Because patient dropout is rarely a patient problem. More often, it is a trial design problem.

References: 

  1. Anastasi, Joyce K et al. “Recruitment and retention of clinical trial participants: understanding motivations of patients with chronic pain and other populations.” Frontiers in pain research (Lausanne, Switzerland) vol. 4 1330937. 28 Mar. 2024, doi:10.3389/fpain.2023.1330937 
  1. The Center for Information and Study on Clinical Research Participation (CISCRP). “2019 Perceptions and Insights Study.” Dec.2019. https://www.ciscrp.org/wp-content/uploads/2019/12/Participation-Experiences-04DEC-1.pdf. Last Accessed July 2026. 
  1. Kelsey, Michelle D et al. “Inclusion and diversity in clinical trials: Actionable steps to drive lasting change.” Contemporary clinical trials vol. 116 (2022): 106740. doi:10.1016/j.cct.2022.106740 
  1. Dobra, Rebecca et al. “A systematic review to identify and collate factors influencing patient journeys through clinical trials.” JRSM open vol. 14,6 20542704231166621. 7 Jun. 2023, doi:10.1177/20542704231166621 
  1. Meskó, Bertalan et al. “Patient Design: The Importance of Including Patients in Designing Health Care.” Journal of medical Internet research vol. 24,8 e39178. 31 Aug. 2022, doi:10.2196/39178 
  1. Geißler, Jan et al. “Patient involvement in clinical trials.” Communications medicine vol. 2 94. 25 Jul. 2022, doi:10.1038/s43856-022-00156-x 
  1. Fischer, Saloumeh K. “Patient-centric clinical trials: collaboration and innovation in bioanalytical and clinical operations.” Bioanalysis vol. 17,4 (2025): 277-280. doi:10.1080/17576180.2025.2458453 
  1. Newlands, R et al. “Why trials lose participants: A multitrial investigation of participants’ perspectives using the theoretical domains framework.” Journal of Clinical Epidemiology, 2021; Vol137, P1-13.